Tag: CardioFocus

CardioFocus Announces Publication of 1-Year ECLIPSE AF Clinical Trial Results

MARLBOROUGH, Mass.–(BUSINESS WIRE)–CardioFocus, Inc., a medical device company dedicated to advancing ablation treatment for cardiac arrhythmias, today announced the publication of the 12-month results from the ECLIPSE AF trial in Circulation: Arrhythmia & Electrophysiology, demonstrating an overall 90.2% 12-month freedom from clinically significant atrial arrhythmia among paroxysmal atrial fibrillation (AF) patients undergoing […]

CardioFocus Announces First Patients Treated with OptiShot™ Pulsed Field Ablation System

December 17, 2024 03:09 PM Eastern Standard Time MARLBOROUGH, Mass.–(BUSINESS WIRE)–CardioFocus, Inc., a medical device company dedicated to advancing ablation treatment for cardiac arrhythmias, today announced the first series of patients treated with the investigational OptiShot™ Pulsed Field Ablation (PFA) System for the treatment of paroxysmal atrial fibrillation as part […]

CardioFocus Announces Pulsed Field Ablation Milestones

MARLBOROUGH, Mass., July 19, 2022 /PRNewswire/ — CardioFocus, Inc., a medical device company dedicated to advancing ablation treatments for atrial fibrillation (Afib), today announced several milestones toward the development of a next generation pulse field ablation (PFA) technology for treatment of AFib, including the formation of a clinical advisory board, filing of […]

CardioFocus Announces Agreement to Acquire Intellectual Property

MARLBOROUGH, Mass., September 14, 2021 – CardioFocus, Inc., a medical device company dedicated to advancing ablation treatments for atrial fibrillation (AFib), announced today that it has entered into an agreement with IsoLase Ltd. to acquire IsoLase’s patent portfolio. The acquisition agreement includes US patents 8,992,514 and 10,517,669 and EU patent […]

CardioFocus Appoints Stephan Ogilvie as Chief Financial Officer

MARLBOROUGH, Mass., June 29, 2021 /PRNewswire/ — CardioFocus, Inc., a medical device company dedicated to advancing ablation treatment for atrial fibrillation (AFib), today announced the appointment of Stephan Ogilvie as its Chief Financial Officer. Mr. Ogilvie’s career spans decades in the medical technology sector and includes leadership roles in sales and marketing and corporate development, […]

CardioFocus Receives Regulatory Approval to Market HeartLight X3 System in Japan

– Japan Lifeline will distribute CardioFocus’ innovative catheter ablation technology for pulmonary vein isolation, the gold standard treatment for atrial fibrillation – Regulatory approval comes as use of catheter ablation technologies for AFib is increasing in Japan at a substantial rate MARLBOROUGH, Mass., June 23, 2021 /PRNewswire/ — CardioFocus, Inc., a medical device […]

CardioFocus Announces Agreement with China Grand Pharmaceutical to Bring HeartLight X3 System to China

– China Grand Pharma will seek regulatory approvals and commercialize CardioFocus’ innovative catheter ablation technology for pulmonary vein isolation – Pulmonary vein isolation is the gold standard treatment for atrial fibrillation MARLBOROUGH, Mass., June 2, 2021 /PRNewswire/ — CardioFocus, Inc., a medical device company dedicated to advancing ablation treatments for atrial fibrillation (AFib), […]

CardioFocus Announces The Publication Of HeartLight X3 Pivotal Study Data

HeartLight® X3 System Has Significantly Shorter Procedure Times for Atrial Fibrillation Ablation MARLBOROUGH, Mass., Feb. 25, 2021 /PRNewswire/ — CardioFocus, Inc., a medical device company dedicated to advancing ablation treatment for atrial fibrillation (AFib), announced today that results from its HeartLight® X3 Pivotal Study were published in the premier journal Circulation: Arrhythmia and Electrophysiology (CircEP), which features […]

CardioFocus Announces Expanded Partnership With Japan Lifeline

HeartLight® X3 Japan Launch Anticipated in Mid-2021 MARLBOROUGH, Mass., Feb. 2, 2021 /PRNewswire/ — CardioFocus, Inc., a medical device company dedicated to advancing ablation treatments for atrial fibrillation (AFib), announced today that it has expanded its existing partnership agreement with Japan Lifeline Co., Ltd. (JLL). The agreement extends the timeframe of the existing distribution […]

CardioFocus® Announces Expanded Distribution Partnership With MicroPort™ CRM To Include Spain And Portugal

MARLBOROUGH, Mass., Jan. 11, 2021 /PRNewswire/ — CardioFocus, Inc., a medical device company dedicated to advancing ablation treatment for atrial fibrillation (AFib), announced today that it has expanded its existing French distribution partnership agreement with MicroPort CRM in France to include both Spain and Portugal. “We are pleased to be represented by MicroPort CRM in France and have been very impressed by […]